» Articles » PMID: 35656022

The Targeting of Noncoding RNAs by Quercetin in Cancer Prevention and Therapy

Overview
Publisher Wiley
Date 2022 Jun 3
PMID 35656022
Authors
Affiliations
Soon will be listed here.
Abstract

The dietary flavonoid quercetin is ubiquitously distributed in fruits, vegetables, and medicinal herbs. Quercetin has been a focal point in recent years due to its versatile health-promoting benefits and high pharmacological values. It has well documented that quercetin exerts anticancer actions by inhibiting cell proliferation, inducing apoptosis, and retarding the invasion and metastasis of cancer cells. However, the exact mechanism of quercetin-mediated cancer chemoprevention is still not fully understood. With the advances in high-throughput sequencing technologies, the intricate oncogenic signaling networks have been gradually characterized. Increasing evidence on the close association between noncoding RNA (ncRNAs) and cancer etiopathogenesis emphasizes the potential of ncRNAs as promising molecular targets for cancer treatment. Available experimental studies indicate that quercetin can dominate multiple cancer-associated ncRNAs, hence repressing carcinogenesis and cancer development. Thus, modulation of ncRNAs serves as a key mechanism responsible for the anticancer effects of quercetin. In this review, we focus on the chemopreventive effects of quercetin on cancer pathogenesis by targeting cancer-relevant ncRNAs, supporting the viewpoint that quercetin holds promise as a drug candidate for cancer chemoprevention and chemotherapy. An in-depth comprehension of the interplay between quercetin and ncRNAs in the inhibition of cancer development and progression will raise the possibility of developing this bioactive compound as an anticancer agent that could be highly efficacious and safe in clinical practice.

Citing Articles

Identifying the Main Components and Mechanisms of Action of L. in the Treatment of Endometrial Cancer Using Network Pharmacology.

Guo W, Wang W, Lei F, Zheng R, Zhao X, Gu Y ACS Omega. 2024; 9(7):8055-8066.

PMID: 38405483 PMC: 10882657. DOI: 10.1021/acsomega.3c08320.


Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications.

Liu Y, Ding W, Wang J, Ao X, Xue J Front Oncol. 2023; 13:1256537.

PMID: 37746261 PMC: 10514911. DOI: 10.3389/fonc.2023.1256537.


Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and mechanisms of action.

Zhan L, Su F, Li Q, Wen Y, Wei F, He Z Front Pharmacol. 2023; 14:1257450.

PMID: 37693915 PMC: 10484417. DOI: 10.3389/fphar.2023.1257450.


Functional Perspective of Leeks: Active Components, Health Benefits and Action Mechanisms.

Xie T, Wu Q, Lu H, Hu Z, Luo Y, Chu Z Foods. 2023; 12(17).

PMID: 37685158 PMC: 10486880. DOI: 10.3390/foods12173225.


Quercetin alleviates tubulointerstitial inflammation by inhibiting exosomes-mediated crosstalk between tubular epithelial cells and macrophages.

Yin D, Cao J, Yang Y, Li Z, Liu H, Tang T Inflamm Res. 2023; 72(5):1051-1067.

PMID: 37039838 DOI: 10.1007/s00011-023-01730-2.


References
1.
Guo X, Gao L, Wang Y, Chiu D, Wang T, Deng Y . Advances in long noncoding RNAs: identification, structure prediction and function annotation. Brief Funct Genomics. 2015; 15(1):38-46. PMC: 5863772. DOI: 10.1093/bfgp/elv022. View

2.
Pisignano G, Ladomery M . Epigenetic Regulation of Alternative Splicing: How LncRNAs Tailor the Message. Noncoding RNA. 2021; 7(1). PMC: 8005942. DOI: 10.3390/ncrna7010021. View

3.
Wang P, Chen D, Ma H, Li Y . LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Onco Targets Ther. 2017; 10:5137-5149. PMC: 5661845. DOI: 10.2147/OTT.S146423. View

4.
Han Y, Wu Z, Wu T, Huang Y, Cheng Z, Li X . Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis. 2016; 7:e2123. PMC: 4823926. DOI: 10.1038/cddis.2015.407. View

5.
Kim D, Khan H, Ullah H, Hassan S, Smejkal K, Efferth T . MicroRNA targeting by quercetin in cancer treatment and chemoprotection. Pharmacol Res. 2019; 147:104346. DOI: 10.1016/j.phrs.2019.104346. View